Advancing excellence in laboratory medicine for better healthcare worldwide

IFCC - Scientific Division (SD)

 

SD Executive Committee Meeting as Conference Call - June 2021

From left to right - top to bottom: 

Philippe Gillery - Chair; Michael Rottmann- Corporate Members Representative; Ian Young- ICHCLR Observer; Karen Phinney - NIST Consultant; Yang Zhen - NIFDC Observer; Chris Burns - NIBSC Consultant; Greg Miller - JCTLM Consultant; Christa Cobbaert - Vice Chair; Paola Bramati- IFCC Office; Barnali Das - Member; Konstantinos Makris - Member;  Smeralda Skerendaj - IFCC Office; Garry John - Secretary; Liesbet Drepez - JRC Observer. 

SD Executive Committee (SD-EC) biographies

The Scientific Division (SD)

A Committee on Standards was established in 1966 "to instigate and promote theoretical and practical developments in the field of standards and standardisation in clinical chemistry - in its broadest sense." During its first decade, the main efforts of the Committee were directed toward (1) analytical nomenclature, (2) reference materials and methods, and (3) quality control. Its achievements during this period are illustrated by the list of publications on these topics. Following a Council decision in 1978, efforts have been made to extend its work to include more subjects of interest both to clinicians and clinical chemists and laboratorians. Accordingly, the name of the Committee was changed to the Scientific Committee and later to the Scientific Division.

The Division and its activities are managed by an Executive Committee. This Committee is responsible for (1) developing a mission statement, (2) developing strategy and tactics, (3) initiating and managing projects, and (4) generating and adhering to its Terms of Reference.

Mission Statement

The mission of the SD is to advance the science of Clinical Chemistry and Laboratory Medicine and to apply it to the practice of Clinical Laboratory Science.

SD Strategy

According to the Statutes of IFCC, the Federation exists to advance the science and practice of Clinical Chemistry and to further its application in the provision of health services and the practice of medicine. The goals to which the Scientific Division is committed are to:

  • Identify research areas of relevance to Clinical Chemistry and Laboratory Medicine and assist the transfer of research results to the profession.
  • Identify scientific and technological problems in current practice and provide solutions and guidelines on how to resolve them.
  • Facilitate the development and transfer of technical innovations to clinical laboratory professionals and clinicians.
  • Facilitate the development and implementation of diagnostic strategies.
  • Establish standards for scientific and technical aspects of good laboratory practice.
  • Facilitate the development of reference measurement processes and the production of reference materials
  • Establish networks of reference laboratories
  • Respond to scientific and technical needs of IFCC Member Societies, IFCC Corporate Members and external agencies.
  • Participate actively in the scientific programmes of IFCC congresses and other scientific meetings.
  • Ensure the quality of IFCC scientific documents.
  • Organise Master Discussions

SD Projects

The SD initiates and manages projects with its own resources or through its Committees and Working Groups. Work is conducted in cooperation with other IFCC units and with relevant National and International Organisations. The SD ensures that each of its Committees and Working Groups are functioning under clear terms of reference together with an agreed schedule of activity. The SD will assist in the development of the project proposals, and will undertake an annual review of progress and review and approve any documents that result from the work.

SD Executive Committee (SD-EC)

NamePositionCountryTermTime in Office
P. GilleryChairFR2nd2020 01 - 2022 12
C.M.  CobbaertVice-ChairNL2nd2020 01 - 2022 12
G. JohnSecretaryUK1st2021 03 - 2023 12
B. DasMemberIN2nd2021 01 - 2023 12
K. MakrisMemberGR2nd2020 01 - 2022 12
M. PlebaniMemberIT2nd2020 01 - 2022 12
M. RottmannCorporate MemberDE1st2020 03 - 2022 12
R.D. JosephsBIPM ObserverFR
L. DeprezEuropean Commission/JRC ObserverBE
I. YoungICHCLR ObserverUK
G. MillerJCTLM Chair / SD ConsultantUS
C. BurnsNIBSC ConsultantUK
Y. ZhenNIFDC ObserverCN
K. PhinneyNIST ConsultantUS

 

Chairs of Scientific Division's Committees and Working Groups

Committees

8.2.06Nomenclature, Properties and Units (C-NPU) in collaboration with International Union of Pure and Applied Chemistry (IUPAC)Y.B.L. Hansen (DK)
8.2.11Molecular Diagnostics (C-MD)P. Ahmad-Nejad (DE)
8.2.23Traceability in Laboratory Medicine (C-TLM)A. Kessler (DE)
8.2.24Reference Intervals and Decision Limits (C-RIDL)Y. Ozarda (TR)
8.2.25Standardization of Thyroid Function Tests (C-STFT)H. Vesper (US)
8.2.26Harmonization of Autoimmune Tests (C-HAT)J. Sheldon (UK)
8.2.26Bone Metabolism (C-BM)E. Cavalier (BE)

Working Groups

8.3.35Standardisation of Hemoglobin A2 (WG-HbA2) - Joint Working Group with ICSH (International Council for Standardization in Haematology)A. Mosca (IT)
8.3.36Carbohydrate-Deficient Transferrin (WG-CDT)J. Deenmamode (UK)
8.3.39Standardisation of Albumin Assay in Urine (WG-SAU) - in collaboration with NIDDK
National Institute of Diabetes and Digestive and Kidney Diseases
J. Seegmiller (US)
8.3.40Standardisation of Pregnancy-Associated Plasma Protein A (WG-PAPP A)S. Wittfooth (UK)
8.3.41Growth-Hormone (WG-hGH)M. Vos (NL)
8.3.42Standardisation of Insulin Assays (WG-SIA) in collaboration with American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD)M. Steffes (US)
J. Seegmiller (US)
8.3.43.Standardisation of Troponin I (WG-TNI)R. Christenson (US)
8.3.49CSF Proteins (WG-CSF)J. Gobom (SE)
8.3.51Commutability in Metrological Traceability (WG-CMT)G. Miller (US)
8.3.53Immunosuppressive Drugs (WG-ID)C. Seger (CH)
8.3.54Apolipoproteins by Mass Spectrometry (WG-APO MS)C. Cobbaert (NL)
8.3.55Pancreatic Enzymes (WG-PE)D. Grote-Koska (DE)
8.3.56Fecal Immunochemical Testing (WG-FIT)S. Benton (UK)
8.3.57Cell free DNA and related circulating biomarkers (WG-cfDNA)R. van Schaik (NL)
8.3.58Procalcitonin (WG-PCT)V. Delatour (FR)
8.3.60Continuous Glucose Monitoring (WG-CGM)G. Freckmann (DE)
8.3.61Development of a Reference Measurement System for sustainable PT/INR Standardization (WG PT/INR)C. Cobbaert (NL)

SD Executive Committe's contacts

CHAIR

Prof. Philippe GILLERY
Service de Biochimie - Pharmacologie - Toxicologie
Pôle de Biologie Médicale et Pathologie
CHU de Reims
Pôle de Biologie Territoriale
Rue du Général Koenig
51092 Reims Cedex
France
Phone: +33 03 26 78 39 52; Fax: +33 03 26 78 84 56
Email: pgillery@chu-reims.fr

VICE-CHAIR

Prof. Christa M. COBBAERT
Clinical Chemist Head of the Department
of Clinical Chemistry
Leiden University Medical Center
Postbus 9600 Postzone E2-P
2300 RC Leiden - The Netherlands
Tel: +31 71 5262278/+31 71 5264483
Fax : +31 71 52666753
E-mail: C.M.Cobbaert@lumc

SECRETARY

Prof. Garry JOHN
Department of Clinical Biochemistry and Immunology
Norfolk and Norwich University Hospital
Norwich  NR4 7UY
UK
Tel: +44 01603 286933
E-mail: GARRY.JOHN@nnuh.nhs.uk

MEMBER

Dr. Barnali DAS
Consultant, Laboratory Medicine
Kokilaben Dhirubhai Ambani Hospital &
Medical Research Institute,
Four Bunglows, Andheri (West)
Mumbai 400053 - India
Tel: +91-22-30970734
Mobile: +91-9324349519
E-mail: barnalidasdr@gmail.com; drbarnalid@gmail.com; Barnali.das@kokilabenhospitals.com

MEMBER

Dr. Konstantinos MAKRIS
Clinical Biochemist
Clinical Biochemistry Department
KAT General Hospital
2 Nikis street, 14561
Kifissia, Athens - Greece
Phone: +30-213-2086701
Mobile: +30-6972207867
e-mail: kostas.makris.km@gmail.com

MEMBER

Prof. Mario PLEBANI
Full Professor of Clinical Biochemistry and
Clinical Molecular Biology
Chief Department of Laboratory Medicine
University Hospital - Padova
Dean of the Medical School
University of Padova - Italy
E-mail: mario.plebani@unipd.it

CORPORATE REPRESENTATIVE

Dr Michael ROTTMANN
Roche Diagnostics GmbH
Director Assay Development
Indication: Tyroid, Sepsis, RA, Growth
Centralised and Point of Care solutions DXRI
Nonnenwald 2
82377 Penzberg  - Germany
Tel.: +49 8856 603322
e-mail: michael.rottmann@roche.com

BUREAU INTERNATIONAL DES POIDS ET MESURES - BIPM OBSERVER

Dr. Ralf D. JOSEPHS
Principal Chemist
Pavillon de Breteuil
92312 Sèvres Cedex
France
Tel.: + 33 (0)1 45 07 70 55
e-mail: ralf.josephs@bipm.org

EUROPEAN COMMISSION - JRC OBSERVER

Dr. Liesbet DEPREZ
Project Officer
European Commission
Directorate General Joint Research Centre
Directorate F – Health, Consumers and Reference Materials - Reference Materials Unit
Retieseweg 111
2440 Geel - Belgium
Tel: +32 (0)14 57 16 34
e-mail: Liesbet.deprez@ec.europa.eu

ICHCLR OBSERVER

Prof. Ian S. YOUNG
Professor of Medicine
Queen's University Belfast
The Center for Public Health
1st floor - ICS B block
Royal Victoria Hospital
Grosvenor Road
BT12 GBJ - Belfast - UK
Tel: +44 02890632743
E-mail:I.Young@qub.ac.uk

JCTLM Chair / SD CONSULTANT

Dr. Greg MILLER
Professor of Pathology
Co-Director of Clinical Chemistry
Director of Pathology Information Systems
Virginia Commonwealth University Health System
Richmond, VA 23298-0286 - USA
Tel:  +1.804.828.0375
Email: greg.miller@vcuhealth.org

NIBSC CONSULTANT

Dr. Chris BURNS
Head, Biotherapeutics Division
National Institute for Biological Standards and Control (NIBSC)
A Centre of the MHRA, Blanche Lane
South Mimms, Potters Bar
Hertfordshire, EN6 3QG - UK
Tel: 01707 641247
Email: Chris.Burns@nibsc.org

NIFDC OBSERVER

Dr. Yang ZHEN
Deputy Director General
National Institutes for Food and Drug Controls (NIFDC)
P.R. CHINA
E-mail: yangzhen@nifdc.org.cn

NIST CONSULTANT

Dr. Karen W. PHINNEY
Leader, Bioanalytical Science Group
Biomolecular Measurement Division
National Institute of Standards and Technology (NIST)
100 Bureau Drive, Stop 8314
Gaithersburg, MD 20899-8314 - USA
Tel.: +1 (301) 975-4457
E-mail: karen.phinney@nist.gov

 
Website developed by Insoft